Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bangasafe PVP-I Spray for COVID-19
NCT04872686Phase 3Completed
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of IVIEW-1502 in coronavirus disease 2019 (COVID-19) (4 arms). Primary endpoints: Viral concentration assessment in Naso-Oropharynx at 24 hours and Effectiveness of 0.6% PVP-I assessment through viral concentration measurement at 24 hours. Started Apr 2021; status: completed.
02
Drugs
IVIEW-1502
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04872686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872686.